+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

LAMEA Autoinjectors Market By Type, By Application, By End Use, By Country, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5233823
  • Report
  • December 2020
  • Region: Middle East, Africa
  • 97 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie, Inc.
  • Amgen, Inc.
  • Biogen, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • MORE
The Latin America, Middle East and Africa Autoinjectors Market is expected to witness market growth of 18.7% CAGR during the forecast period (2020-2026).

Epinephrine is considered the first line of treatment for allergic reactions or anaphylaxis. Pharmaceutical companies are bringing technologically advanced epinephrine autoinjectors (EAIs) treatment of anaphylaxis. With the advancement in technology including portable devices, innovative designs, autoinjectors with two auto-injectable doses in one device, autoinjectors made with a 0.5- or 0.75-mg dose of epinephrine for larger adults, the autoinjectors are experiencing higher rate of adoptability.

Also, autoinjectors made with a 0.1-mg dose of epinephrine for infants, autoinjectors with enhanced temperature stability and extended shelf life for epinephrine, weather-resistant casing, and devices that can update patients that the dosage was successfully delivered makes the device more user friendly. Factors that are being focused on for improvement of autoinjectors are removal force of safety cap, override force, ejection time, ejection dosage, needle activation force, needle length, dose setting & audible click detection. These technological advancements are anticipated to drive the adoption of autoinjectors significantly in the coming years.

The existing COVID-19 pandemic has brought about the implementation of a new set of protocols that target to decrease patient visits to hospitals and clinics if it is not emergency conditions in order to prevent the spread of the virus. In such a situation, the inclination for home-use autoinjectors has increased among patients who are suffering from allergies and chronic illnesses. This also safeguards susceptible high-risk populations from exposure to the virus while visiting to hospital.

Autoinjectors are being advanced to support improved concentrations and viscosity of drugs to lessen administration frequency, therefore growing adherence to acclaimed drug protocols. These factors facilitate an opportunity for the growth of the market of autoinjectors in the present COVID-19 scenario.

Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type
  • Disposable autoinjectors
  • Reusable autoinjectors
By Application
  • Anaphylaxis
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Other Applications
By End Use
  • Hospitals & Clinics
  • Home care settings
By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • Sanofi S.A.
  • Becton, Dickinson and Company
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • Ypsomed AG
  • AbbVie, Inc.
  • Biogen, Inc.
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Amgen, Inc.
  • Biogen, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Autoinjectors Market, by Type
1.4.2 LAMEA Autoinjectors Market, by Application
1.4.3 LAMEA Autoinjectors Market, by End Use
1.4.4 LAMEA Autoinjectors Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Geographical Expansions
3.2.4 Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, May - 2020, Nov) Leading Players

Chapter 4. LAMEA Autoinjectors Market by Type
4.1 LAMEA Disposable autoinjectors Market by Country
4.2 LAMEA Reusable autoinjectors Market by Country

Chapter 5. LAMEA Autoinjectors Market by Application
5.1 LAMEA Anaphylaxis Market by Country
5.2 LAMEA Rheumatoid Arthritis Market by Country
5.3 LAMEA Multiple Sclerosis Market by Country
5.4 LAMEA Other Application Market by Country

Chapter 6. LAMEA Autoinjectors Market by End Use
6.1 LAMEA Hospitals & Clinics Autoinjectors Market by Country
6.2 LAMEA Home care settings Autoinjectors Market by Country

Chapter 7. LAMEA Autoinjectors Market by Country
7.1 Brazil Autoinjectors Market
7.1.1 Brazil Autoinjectors Market by Type
7.1.2 Brazil Autoinjectors Market by Application
7.1.3 Brazil Autoinjectors Market by End Use
7.2 Argentina Autoinjectors Market
7.2.1 Argentina Autoinjectors Market by Type
7.2.2 Argentina Autoinjectors Market by Application
7.2.3 Argentina Autoinjectors Market by End Use
7.3 UAE Autoinjectors Market
7.3.1 UAE Autoinjectors Market by Type
7.3.2 UAE Autoinjectors Market by Application
7.3.3 UAE Autoinjectors Market by End Use
7.4 Saudi Arabia Autoinjectors Market
7.4.1 Saudi Arabia Autoinjectors Market by Type
7.4.2 Saudi Arabia Autoinjectors Market by Application
7.4.3 Saudi Arabia Autoinjectors Market by End Use
7.5 South Africa Autoinjectors Market
7.5.1 South Africa Autoinjectors Market by Type
7.5.2 South Africa Autoinjectors Market by Application
7.5.3 South Africa Autoinjectors Market by End Use
7.6 Nigeria Autoinjectors Market
7.6.1 Nigeria Autoinjectors Market by Type
7.6.2 Nigeria Autoinjectors Market by Application
7.6.3 Nigeria Autoinjectors Market by End Use
7.7 Rest of LAMEA Autoinjectors Market
7.7.1 Rest of LAMEA Autoinjectors Market by Type
7.7.2 Rest of LAMEA Autoinjectors Market by Application
7.7.3 Rest of LAMEA Autoinjectors Market by End Use

Chapter 8. Company Profiles
8.1 Eli Lilly and Company
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Geographical Expansions:
8.2 GlaxoSmithKline PLC (GSK)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.1 Recent strategies and developments:
8.2.1.1 Approvals:
8.3 Merck Group
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.4 Sanofi S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Approvals:
8.4.5.3 Product Launches and Product Expansions:
8.5 Becton, Dickinson and Company
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Product Launches and Product Expansions:
8.6 Teva Pharmaceutical Industries Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.6.5.3 Approvals:
8.7 Amgen, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expense
8.7.4 Recent strategies and developments:
8.7.4.1 Product Launches and Product Expansions:
8.8 Ypsomed AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 AbbVie, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.10. Biogen, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
Note: Product cover images may vary from those shown
3 of 4
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • Sanofi S.A.
  • Becton, Dickinson and Company
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • Ypsomed AG
  • AbbVie, Inc.
  • Biogen, Inc.
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll